Sankar et al. demonstrated that a non-competitive LSD1 inhibitor, HCI2509, disrupted transcriptional profiles and malignant characteristics of EWS/FLI- and EWS/ERG-containing Ewing sarcoma [15] in preclinical evaluations. This evidence concerns the gene ERG and Ewing sarcoma.